Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
morphine + bupivacaine + dexmedetomidine + etoricoxib + paracetamol
- Development stage
- Unknown
- Lead developer
- Udayana University
- Modality
- Small Molecules
- Administration
- Intravenous, Epidural, Oral
01
Overview
This multimodal analgesia regimen was developed and studied by Udayana University for the management of acute postoperative pain, specifically in patients undergoing elective hysterectomy. The regimen is designed to target multiple pain and inflammatory pathways to reduce peripheral and central sensitization, thereby preventing the transition from acute to chronic postoperative pain. It consists of a combination of several pharmacological agents: morphine (an opioid agonist administered via patient-controlled analgesia), bupivacaine (a local anesthetic sodium channel blocker), dexmedetomidine (an alpha-2 adrenergic agonist), etoricoxib (a selective COX-2 inhibitor), and paracetamol (a non-opioid analgesic). The protocol utilizes various routes of administration, including intravenous, epidural, and oral, to optimize analgesic efficacy and modulate inflammatory biomarkers such as MCP-1, BDNF, and microRNA-124.
- Other names
- Multimodal analgesia (Udayana University regimen)
02
Targets
ADRA2A (α2A)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on morphine + bupivacaine + dexmedetomidine + etoricoxib + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on morphine + bupivacaine + dexmedetomidine + etoricoxib + paracetamol.